SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s Laboratories launches Sodium Nitroprusside Injection

30 Dec 2019 Evaluate

Dr. Reddy's Laboratories has launched Sodium Nitroprusside Injection, 50 mg/2 ml (25 mg/ml) Single-dose Vial, the therapeutic generic equivalent of Nitropress (sodium nitroprusside) Injection, 50 mg/2ml vial, approved by the U.S. Food and Drug Administration (USFDA).

The Nitropress brand and generics had U.S. sales of approximately $8 million MAT for the most recent twelve months ending in October 2019 according to IQVIA Health. The company’s Sodium Nitroprusside Injection is available in single-dose 50 mg/2 ml (25 mg/ml) vials.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.

Dr. Reddys Lab Share Price

1220.45 -0.30 (-0.02%)
22-Apr-2026 11:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1659.75
Dr. Reddys Lab 1220.45
Cipla 1230.50
Zydus Lifesciences 930.70
Lupin 2313.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×